<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334854</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-EPSSG-NRSTS-2005</org_study_id>
    <secondary_id>CDR0000482277</secondary_id>
    <secondary_id>EU-20620</secondary_id>
    <secondary_id>EUDRACT-2005-001139-31</secondary_id>
    <secondary_id>UKCCSG-CTA-21275/0215/001/0001</secondary_id>
    <secondary_id>CCLG-EpSSG-STS-2006-03</secondary_id>
    <nct_id>NCT00334854</nct_id>
  </id_info>
  <brief_title>Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma</brief_title>
  <official_title>Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Paediatric Soft Tissue Sarcoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Association for Pediatric Hematology Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cooperative Weichteilsarkom Studie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Childhood Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
      Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination
      chemotherapy with or without radiation therapy before surgery may make the tumor smaller and
      reduce the amount of normal tissue that needs to be removed. Giving radiation therapy after
      surgery may kill any tumor cells that remain after surgery.

      PURPOSE: This phase III trial is studying how well giving ifosfamide and doxorubicin,
      radiation therapy, and/or surgery works in treating young patients with localized soft tissue
      sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine survival rates (event-free survival and overall survival [OS]) and the pattern
           of treatment failure in patients with synovial sarcoma or adult-type soft tissue sarcoma
           treated with ifosfamide and doxorubicin hydrochloride, radiotherapy, and/or surgery.

        -  Determine the role of ifosfamide and doxorubicin hydrochloride in improving the response
           rate in patients with unresectable synovial sarcoma or adult-type soft tissue sarcoma.

      Secondary

        -  Evaluate clinical/pathological prognostic factors, particularly tumor grade and
           radiological and pathological response to neoadjuvant treatment.

        -  Determine the impact of omitting adjuvant chemotherapy in patients with low-risk
           synovial sarcoma (tumor &lt; 5 cm).

        -  Determine the role of adjuvant chemotherapy in improving the metastases-free survival
           and OS in patients with adult-type soft tissue sarcoma (Intergroup Rhabdomyosarcoma
           Study [IRS] postsurgical grouping system I-II, tumor grade 3, tumor size &gt; 5 cm).

      OUTLINE: This is a nonrandomized, prospective, historically controlled, multicenter study.
      Patients with synovial sarcoma are stratified according to the Intergroup Rhabdomyosarcoma
      Study (IRS) postsurgical grouping system (I vs II vs III) and tumor size ( ≤ 5 cm vs &gt; 5 cm).
      Patients with adult-type soft tissue sarcoma are stratified according to the IRS postsurgical
      grouping system (I vs II vs III), tumor size ( ≤ 5 cm vs &gt; 5 cm), and tumor grade (G1 vs G2
      vs G3). Patients are assigned to 1 of 9 treatment groups according to disease and
      stratification.

      Synovial sarcoma

        -  Group 1 (IRS group I, tumor ≤ 5 cm): Patients undergo surgical resection of tumor.

        -  Group 2 (IRS group I, tumor &gt; 5 cm): Patients receive ifosfamide IV over 3 hours on days
           1-3 and doxorubicin hydrochloride IV over 4-6 hours on days 1 and 2 (IFO-DOX). Treatment
           repeats every 21 days for 4 courses.

        -  Group 3 (IRS group II, tumor ≤ 5 cm): Patients receive 3 courses of IFO-DOX. After the
           completion of chemotherapy, patients undergo radiotherapy 5 days a week for 5-6 weeks.

        -  Group 4 (IRS group II, tumor &gt; 5 cm): Patients receive 3 courses of IFO-DOX. Patients
           then receive ifosfamide alone IV over 3 hours on days 1-3. Treatment with ifosfamide
           repeats every 21 days for 2 courses. Patients also receive concurrent radiotherapy
           (concurrently with ifosfamide) 5 days a week for 5-6 weeks. After completion of
           radiotherapy, patients receive 1 additional course of IFO-DOX.

        -  Group 5 (IRS group III, N1): Patients receive 3 courses of IFO-DOX. Patients with no
           response to chemotherapy receive 1 of the following local therapies:

             -  Delayed complete resection*

             -  Radiotherapy (as in group 3) followed by surgery*

             -  Delayed complete resection* followed by radiotherapy** (as in group 3)

             -  Delayed incomplete resection* followed by radiotherapy** (as in group 3)

             -  Radiotherapy (as in group 3) Patients with major or minor response to chemotherapy
                receive 2 courses of ifosfamide with concurrent radiotherapy followed by 1
                additional course of IFO-DOX (as in group 4, above).

      NOTE: * Patients undergo surgery 5 weeks after completion of chemotherapy and/or
      radiotherapy.

      NOTE: **Patients undergo radiotherapy beginning &lt; 21 days after surgery.

      Adult-type soft tissue sarcoma

        -  Group 1 (IRS group I, tumor ≤ 5 cm): Patients undergo surgical resection of tumor.

        -  Group 2 (IRS group I, tumor &gt; 5 cm): Patients receive therapy according to tumor grade:

             -  G1 disease: Patients undergo surgical resection.

             -  G2 disease: Patients undergo radiotherapy 5 days a week for 5-6 weeks.

             -  G3 disease: Patients receive the following sequential treatment: 3 courses of
                IFO-DOX followed by 2 courses of ifosfamide with concurrent radiotherapy followed
                by 1 course of IFO-DOX.

        -  Group 3 (IRS group II, N0): Patients receive therapy according to tumor grade:

             -  G1 disease: Patients undergo surgical resection.

             -  G2-3 disease (≤ 5 cm) and G2 disease (&gt; 5 cm): Patients undergo radiotherapy 5 days
                a week for 5-6 weeks.

             -  G3 disease (&gt; 5 cm): Patients undergo sequential treatment (as in group 2,
                adult-type soft tissue sarcoma).

        -  Group 4 (IRS group III, N1): Patients receive 3 courses of IFO-DOX. Patients with no
           response to chemotherapy receive local therapy (as in group 5 synovial sarcoma).
           Patients with major or minor response to chemotherapy receive 2 courses of ifosfamide
           with concurrent radiotherapy followed by 2 additional courses of IFO-DOX (as in group 4,
           synovial sarcoma).

      After completion of study therapy, patients are followed periodically for up to 10 years.

      PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Local relapse-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Metastases-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (complete response, very good partial response [PR], PR, minor PR, and stable disease)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Childhood Malignant Fibrous Histiocytoma of Bone</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed synovial sarcoma or adult-type soft-tissue sarcoma

               -  Adult-type soft tissue sarcoma includes any of the following:

                    -  Fibrosarcoma (adult-type)

                         -  No infantile fibrosarcoma

                    -  Malignant peripheral nerve sheath tumor

                         -  Malignant schwannoma

                         -  Neurofibrosarcoma

                    -  Epithelioid sarcoma

                    -  Leiomyosarcoma

                    -  Clear cell sarcoma

                    -  Liposarcoma

                    -  Alveolar soft-part sarcoma

                    -  Malignant fibrous histiocytoma

                    -  Hemangiopericytoma

                    -  Angiosarcoma

                    -  Dermatofibrosarcoma protuberans

                    -  Mesenchymal chondrosarcoma

          -  No borderline tumors (e.g., hemangioendothelioma)

          -  No small round cell tumors (e.g., extraosseous Ewing's sarcoma/primitive
             neuroectodermal tumor or desmoplastic small round cell tumor)

          -  Post-irradiation soft-part sarcomas allowed

          -  Diagnostic surgery performed within the past 8 weeks (for patients who require
             adjuvant chemotherapy)

          -  No evidence of metastatic disease

               -  Involved locoregional lymph nodes are allowed

        PATIENT CHARACTERISTICS:

          -  No prior malignancy

          -  No pre-existing illness precluding study treatment*

          -  Normal renal function (nephrotoxicity grade 0-1)*

          -  No history of cardiac disease*

          -  Normal shortening fraction (&gt; 28%)*

          -  Ejection fraction &gt; 47%* NOTE: * For patients who require adjuvant chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  No prior cancer treatment except primary surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Ferrari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Modesto Carli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joern Treuner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Olgahospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernadette Brennan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Manchester Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Max Van Noesel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus MC - Sophia Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Ladenstein, MD</last_name>
      <phone>43-1-404-700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Esperance</name>
      <address>
        <city>Montegnee</city>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Francotte, MD</last_name>
      <phone>32-4-224-9111</phone>
      <email>nadine.francotte@chc.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Rechnitzer, MD, PhD</last_name>
      <phone>45-3545-1368</phone>
      <email>rechnitzer@rh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Orbach, MD</last_name>
      <phone>33-14-432-4550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne O'Meara, MD</last_name>
      <phone>353-409-6659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soledad Gallego, MD, PhD</last_name>
      <phone>34-93-489-3090</phone>
      <email>sgallego@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustaf Ljungman, MD</last_name>
      <phone>46-18-611-5586</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Niggli, MD</last_name>
      <phone>41-44-266-7823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B16 8ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hobin, MD</last_name>
      <phone>44-121-454-4851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. C. G. Stevens, MD</last_name>
      <phone>44-117-342-0205</phone>
      <email>m.stevens@bristol.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Williams, MD</last_name>
      <phone>44-1223-256-298</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Glaser, MD</last_name>
      <phone>44-113-206-4984</phone>
      <email>adam.glaser@leedsth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Visser, MD</last_name>
      <phone>44-116-258-5309</phone>
      <email>johannes.visser@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather P. McDowell, MD</last_name>
      <phone>44-151-293-3679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1T 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ananth Shankar, MD</last_name>
      <phone>44-20-7380-9300 ext. 9950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Chisholm, MD</last_name>
      <phone>44-20-7829-7924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Brennan, MD</last_name>
      <phone>44-161-922-2227</phone>
      <email>bernadette.brennan@cmmc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Hale, MD</last_name>
      <phone>44-191-282-4101</phone>
      <email>j.p.hale@ncl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hewitt, MD, BSc, FRCP, FRCPCH</last_name>
      <phone>44-115-924-9924 ext. 63394</phone>
      <email>martin.hewitt@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Wheeler, MD</last_name>
      <phone>44-186-522-1066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary P. Gerrard, MBChB, FRCP, FRCPCH</last_name>
      <phone>44-114-271-7366</phone>
      <email>mary.gerrard@sch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice A. Kohler, MD, FRCP</last_name>
      <phone>44-23-8079-6942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Pritchard-Jones, MD</last_name>
      <phone>44-20-8661-3452 ext 3498</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony McCarthy, MD</last_name>
      <phone>44-289-063-3631</phone>
      <email>anthonymcarthy@royalhospital.n.i.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek King, MD</last_name>
      <phone>44-1224-681-818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Hamish Wallace, MD</last_name>
      <phone>44-131-536-0426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind D. Ronghe, MD</last_name>
      <phone>44-141-201-9309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Traunecker, MD, PhD</last_name>
      <phone>44-29-2074-2285</phone>
      <email>heidi.traunecker@cardiffandvale.wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2006</study_first_submitted>
  <study_first_submitted_qc>June 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>childhood alveolar soft-part sarcoma</keyword>
  <keyword>childhood angiosarcoma</keyword>
  <keyword>childhood epithelioid sarcoma</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>childhood leiomyosarcoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>childhood neurofibrosarcoma</keyword>
  <keyword>localized childhood malignant fibrous histiocytoma of bone</keyword>
  <keyword>childhood malignant hemangiopericytoma</keyword>
  <keyword>dermatofibrosarcoma protuberans</keyword>
  <keyword>chondrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Histiocytoma, Benign Fibrous</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

